Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 14/20 | 0.81 |
| ▸ | CNR1 | P21554 | 4/20 | 0.45 |
| ▸ | CNR2 | P34972 | 3/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23972141 | 0.90 | CHRM1 (1.00) | CHRM1 | |
| SCHEMBL21859106 | 0.81 | CHRM1 (0.61) | CHRM1CNR1CNR2 | |
| SCHEMBL21859041 | 0.81 | CHRM1 (0.66) | CHRM1CNR1CNR2 | |
| SCHEMBL22322417 | 0.81 | CHRM1 (0.78) | CHRM1 | |
| SCHEMBL21859015 | 0.81 | CHRM1 (0.67) | CHRM1CNR1 | |
| SCHEMBL21938750 | 0.81 | CHRM1 (0.61) | CHRM1CNR1CNR2 | |
| SCHEMBL23972176 | 0.80 | CHRM1 (0.83) | CHRM1 | |
| SCHEMBL23972179 | 0.79 | CHRM1 (0.59) | CHRM1CNR2 | |
| SCHEMBL21938254 | 0.78 | CHRM1 (0.55) | CHRM1 | |
| SCHEMBL23972160 | 0.78 | CHRM1 (0.80) | CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3867254-B1 | PYRROLO-PYRIDAZINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LTD (IN) | 2023-05-31 | — | — | EP | disclosed |
| US-20210340148-A1 | PYRROLO-PYRIDAZINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | SUVEN LIFE SCIENCES LIMITED (IN) | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340148-A1 | PYRROLO-PYRIDAZINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | CHRM1, CHRM5, CHRM2 | CHRM1 1/4885CNR1 68/4885CNR2 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.